JACOBS LEVY EQUITY MANAGEMENT, INC
Position in TCRX — TScan Therapeutics, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in TCRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,028,809
+$212,370 QoQ
Shares Held
1,049,806
+29.9% QoQ
Ownership
1.55%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#10
of 60 holders
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 90%
Shared 0%
None 10%
Common Shares in TCRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. TCRX ranks #53 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in TCRX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,028,809 | 1,049,806 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $816,439 | 808,356 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $188,152 | 188,152 | Shares | Sole | 2026-02-13 | |
| 2024-12-31 | $57,611 | 18,951 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $515,131 | 103,440 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||